COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Evaluation of Neuroprotective Effect of Minocycline (minocyclin &RD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01297816
Recruitment Status : Unknown
Verified December 2010 by Shahid Beheshti University of Medical Sciences.
Recruitment status was:  Recruiting
First Posted : February 17, 2011
Last Update Posted : February 17, 2011
Information provided by:
Shahid Beheshti University of Medical Sciences

Brief Summary:

This process appears as a incredible and progressive event that will not stop till reattachment of RPE and neurosensory retina happened .

Process of degeneration begins from first hours of RD (Retinal Detachment) establishment Neuroprotection of photoreceptor following RD is a novel and debatable discussion encountered in recent years .

How to stop this phenomena and neuroprotective agent role in this issue are a new interest of researcher.

In the study the investigators are planning to perform a clinical trial to demonstrate the minocycline neuroprotective effect in a double blind design as this impact has been implicated previously in a animal study

Condition or disease Intervention/treatment Phase
Retinal Detachment Drug: placebo Drug: Minocycline Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: Evaluation of Minocycline Neuro Protective Role in Retinal Detachment Surgery
Study Start Date : December 2010
Estimated Primary Completion Date : December 2010
Estimated Study Completion Date : April 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Placebo Comparator: placebo
Drug: placebo
100mg,BD, fo three month

Placebo Comparator: minocyclin Drug: Minocycline

Primary Outcome Measures :
  1. BCVA [ Time Frame: changes of BCVA in 3 month ]
    outcome method of measurement: Snellen chart

Secondary Outcome Measures :
  1. finding of ERG changes [ Time Frame: 3 months ]
    outcome method of measurement: ERG( testes)

  2. finding of OCT changes [ Time Frame: 3 months ]
    outcome method of measurement: OCT

  3. finding of FAF changes [ Time Frame: 3 months ]
    outcome method of measurement: FAF( testes)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   8 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • age over 8 years old
  • gender of both sex
  • normal liver and renal function
  • informed consent received from all patients
  • no pregnancy and no lactation
  • minimal sun exposure

Exclusion Criteria:

  • old RD
  • diabetic retina
  • previous retinal surgery CRF& liver disfunction RD + PVR > B Hyper sensitivity to tetracycline History previous MPC or PRP Patients unsuccessful SB (retina is off )

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01297816

Layout table for location information
Iran, Islamic Republic of
Labbafinejad medical center Recruiting
Tehran, Iran, Islamic Republic of
Contact: Mohsen Azarmina, Associate Professor    00982122585952   
Principal Investigator: Mohsen Azarmina, Associate Professor         
Sponsors and Collaborators
Shahid Beheshti University of Medical Sciences
Layout table for additonal information
Responsible Party: Mohsen Azarmina, Ophthalmic Research center Identifier: NCT01297816    
Other Study ID Numbers: 89122
First Posted: February 17, 2011    Key Record Dates
Last Update Posted: February 17, 2011
Last Verified: December 2010
Additional relevant MeSH terms:
Layout table for MeSH terms
Retinal Detachment
Retinal Diseases
Eye Diseases
Anti-Bacterial Agents
Anti-Infective Agents